Latest China News

Audeara Ltd reported a strong Q2 FY26 with revenues up 274% year-on-year, securing key regulatory approval in China and expanding its global licensing footprint.

Everest Metals Corporation, in partnership with Edith Cowan University, has won a $490,500 grant to accelerate its innovative rubidium extraction technology at the Mt Edon project, positioning Australia to establish its first sovereign rubidium supply.

Fulcrum Lithium has secured permits for an extensive Phase 3 drilling program at its Alkali Flats project in Nevada, aiming to expand and refine its lithium resource amid a robust market rally.

PhosCo Ltd reports significant progress at its Gasaat Phosphate Project in Tunisia, backed by a €1 million EBRD grant and promising drilling outcomes at KM and SAB deposits. The company is well positioned amid rising global phosphate demand and tightening supply.

Australian Rare Earths has demonstrated a low-risk, scalable process producing a high-purity mixed rare earth oxide with 99.9% recovery, positioning its Koppamurra project as a strategic supplier amid tightening global rare earth markets.

BHP has reported a robust operational half-year, setting new production records and raising its copper output forecast for FY26 amid strong commodity prices.

Telix Pharmaceuticals has achieved a key milestone with China’s NMPA accepting its New Drug Application for Illuccix, a prostate cancer imaging agent backed by strong Phase 3 data. This paves the way for Telix to enter a rapidly growing Chinese market alongside its global approvals.

VRX Silica Limited has locked in six binding offtake contracts totaling nearly 1 million tonnes per annum and appointed a new CEO, marking significant progress for its Arrowsmith North silica sand project.

Tungsten Mining NL advances its Mt Mulgine project with a robust scoping study, revealing a globally significant multi-critical mineral deposit poised to meet soaring tungsten demand amid supply constraints.

Cambium Bio has locked in a A$2.4 million strategic investment from Zheng Yang Biomedical Technology, reinforcing its push into pivotal Phase 3 trials for its dry eye disease treatment.

Yancoal has reported record coal production and sales for 2025, achieving near the top of its guidance range with improved realised prices despite challenging market conditions. The company’s robust cash position and disciplined cost management position it well for future growth.

The a2 Milk Company has responded to an ASX price query denying any undisclosed information behind recent share price moves, attributing the volatility to China’s latest birth statistics.